PCSK9遗传变异,大脑动脉样硬化和血管改造
Daniela Coggi1, Joey Ward2, Chiara Macchi3
1Centro Cardiologico Monzino, Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Lombardy, Italy.
Open heart
|October 10, 2025
概括
在PCSK9的遗传变异影响LDL-C水平和动脉厚度. 这表明PCSK9的遗传变异会影响动脉样硬化,与预防心血管疾病的PCSK9抑制剂益处保持一致.
科学领域:
- 心血管遗传学 心血管遗传学
- 代谢性疾病研究研究
- 动脉样硬化研究 研究动脉样硬化
背景情况:
- 蛋白转化酶亚素/素9型 (PCSK9) 调节胆固醇的新陈代谢.
- PCSK9变种影响低密度脂蛋白胆固醇 (LDL-C) 水平和心血管疾病 (CVD) 风险.
- 这项研究检查了PCSK9遗传变体与动脉动脉样硬化之间的联系.
研究的目的:
- 为了调查PCSK9变异所示的基因决定的LDL-C水平是否会影响常见的动脉动脉样硬化.
- 评估PCSK9遗传变体与常见的动脉内膜介质厚度 (CC-IMT) 之间的关联.
主要方法:
- 对3040名欧洲参与者 (IMPROVE研究) 和49,088名个人 (英国生物银行) 的分析.
- 使用超声学测量常见的动脉内膜介质厚度 (CC-IMT).
- 四种PCSK9变异的基因型定型和脂质降低基评分 (LLAS) 的计算.
主要成果:
- 在IMPROVE队列中,PCSK9变异对LDL-C和PCSK9水平产生了预期的影响.
- 在女性 (IMPROVE) 和男性/整体 (UKB) 中,LLAS与CC-IMT措施有负相关性 (p<0.05).
- 在IMPROVE和英国生物库队列之间观察到可比的效果大小.
结论:
- PCSK9位点中的遗传变异与改变的LDL-C水平有关.
- PCSK9的遗传变异会影响常见的动脉内膜介质厚度,这是动脉样硬化的一个标志.
- 这些发现支持PCSK9在动脉样硬化中的作用以及PCSK9抑制剂对心血管事件的疗效.
相关概念视频
Coronary Artery Disease I: Introduction
878
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
878
Single Nucleotide Polymorphisms-SNPs
17.9K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
17.9K
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
389
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
389
Comparing Copy Number Variations and SNPs
18.6K
Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
18.6K
Coronary Artery Disease II: Pathophysiology
367
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
367
Atherosclerosis III: Management
319
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
319


